# Panblok H7 Vaccine Adjuvanted With AS03 or MF59

> **NCT03283319** · PHASE2 · COMPLETED · sponsor: **Biomedical Advanced Research and Development Authority** · enrollment: 366 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** 3.75 ug Panblok H7
- **BIOLOGICAL:** 7.5 ug Panblok H7
- **BIOLOGICAL:** 15 ug Panblok H7
- **BIOLOGICAL:** MF59
- **BIOLOGICAL:** AS03

## Key facts

- **NCT ID:** NCT03283319
- **Lead sponsor:** Biomedical Advanced Research and Development Authority
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2017-12-15
- **Final completion:** 2018-11-09
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2020-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283319, "Panblok H7 Vaccine Adjuvanted With AS03 or MF59". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03283319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*